Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. Chief Operating Officer Douglas J. Seith reported equity compensation and related tax withholding in company stock. On March 1, 2026, he received 42,386 shares of common stock as a restricted stock award that vests in three equal annual installments. He also acquired 25,532 shares through the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from these vestings, he transferred 22,948 shares back to the company at $31.26 per share. Following these transactions, he directly owned 229,340 shares of AtriCure common stock.
AtriCure, Inc.’s Chief Legal Officer, Karl S. Dahlquist, reported equity compensation and related tax withholding transactions in company common stock. He acquired 27,991 shares through a restricted stock award and 15,198 shares through the vesting of a performance share award under the 2023 Stock Incentive Plan.
According to the filing, one third of the restricted stock will vest on each of the first, second, and third anniversaries of the grant date. The performance share award vested after company performance goals and service requirements were met.
Dahlquist also disposed of 15,687 shares at a price of $31.26 per share by transferring them back to the company to satisfy tax withholding obligations arising from the vesting and release of earlier restricted stock or performance share awards.
AtriCure, Inc. develops and sells medical devices for surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post‑operative pain control. Its products are used in open‑heart, minimally invasive, and hybrid procedures, and are sold mainly through a direct sales force in the U.S. and key international markets.
The company’s portfolio includes Isolator Synergy and EnCompass RF clamps, EPi‑Sense hybrid ablation systems, AtriClip LAA exclusion devices, and cryoICE/cryoSPHERE/cryoXT probes for Cryo Nerve Block pain therapy. AtriCure supports these products with extensive clinical trials such as CONVERGE, LeAAPS, BoxX‑NoAF, HEAL‑IST and ICE‑AFIB, and invests heavily in physician training and education.
AtriCure highlights large underpenetrated markets in Afib surgery, LAA exclusion, and non‑opioid pain management, while noting competitive, regulatory, reimbursement and execution risks. As of June 30, 2025, non‑affiliate common stock held a market value of about $1,571.5 million, with 49,809,901 shares outstanding as of February 12, 2026.
AtriCure, Inc. reported strong growth for the fourth quarter and full year 2025 while moving toward sustained profitability. Fourth quarter 2025 revenue was $140.5 million, up 13.1% year over year, with net income of $1.8 million and adjusted EBITDA of $19.9 million. Full year 2025 revenue reached $534.5 million, an increase of 14.9%, and gross margin improved to 75.0%. The company narrowed its net loss to $11.4 million while nearly doubling adjusted EBITDA to $61.8 million. Management projects 2026 revenue of $600–$610 million, full year positive net income, and adjusted EBITDA of $80–$82 million, with expected adjusted EPS between $0.09 and $0.15 and GAAP EPS between $0.00 and $0.04.
Hood River Capital Management LLC filed Amendment No. 2 to a Schedule 13G reporting its beneficial ownership of AtriCure, Inc. common stock. The firm reports holding 3,096,611 shares, representing 6.23% of the outstanding common stock as of the event date.
Hood River discloses sole power to dispose of these 3,096,611 shares but no power to vote them. It certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of AtriCure.
AtriCure, Inc. entered into a First Amendment to its credit agreement with JPMorgan Chase Bank and other lenders, extending the term of its asset-based revolving credit facility by three years. The amended credit agreement maintains an asset-based revolving credit facility of up to $125 million, with the option to increase commitments by up to $40 million, for a potential total of $165 million. A portion of the facility not exceeding $5 million is available for letters of credit, and swingline loans may be advanced at the Administrative Agent’s discretion. The amendment also reduces the overall interest rate on loans under the facility and removes the minimum utilization financial covenant. The facility is secured by a first priority security interest in substantially all borrower assets and is guaranteed by the company and its material domestic subsidiaries, and it will be used to finance working capital and general corporate purposes.
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported a charitable gift of 4,000 shares of AtriCure common stock on 12/10/2025. The transfer is coded as a gift and recorded at a price of $0, reflecting that no consideration was received for the donation. After this transaction, he beneficially owns 687,377 shares directly, with an additional 9,310 shares held by his children and 2,250 shares held by his parents, which he reports as indirect holdings while disclaiming beneficial ownership except for his pecuniary interest.
AtriCure, Inc. (ATRC) director reports option exercises and share sales. On 11/24/2025, the reporting person exercised 5,033 non-qualified stock options at $19.95 per share and sold 5,033 shares of common stock at a weighted average price of $37.32 per share. On 11/25/2025, they exercised an additional 4,967 options at $19.95 and sold 4,967 shares at $38.00 per share.
After these transactions, the director beneficially owned 34,374 shares of AtriCure common stock directly and held 25,000 non-qualified stock options. The options exercised on these dates were originally granted on November 11, 2016 and vest over four years, with 25% after one year and the remainder in monthly installments over the next three years.
AtriCure, Inc. (ATRC) reported an insider stock transaction by its Chief Marketing & Strategy Officer. On 11/26/2025, the officer sold 5,166 shares of AtriCure common stock in an open market transaction coded "S" for sale.
The reported sale price is a weighted average of $37.29 per share, with individual trades executed at prices ranging from $36.51 to $38.44 per share. After this transaction, the officer beneficially owns 78,798 shares of AtriCure common stock, held directly.
AtriCure, Inc. (ATRC) reported an insider share sale by a director. On 11/21/2025, the reporting person sold 3,000 shares of AtriCure common stock in an open-market transaction coded as a sale. The weighted average sale price was $35.72 per share, with individual trade prices ranging from $35.71 to $35.76.
Following this transaction, the director beneficially owns 11,371 AtriCure shares, held directly. The filing notes that detailed trade data for the individual prices and share amounts within the reported range will be provided upon request to the SEC staff, the issuer, or any security holder.